If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> ARCHIVE<br /> VOLUME 113 NUMBER 1 JANUARY 2018<br /> www.nature.com/ajg<br /> OFFICIAL PUBLICATION OF THE AMERICAN COLLEGE OF GASTROENTEROLOGY<br /> EDITORS: Brian E. Lacy, PhD, MD, FACG and Brennan Spiegel, MD, MSHS, FACG<br /> January 2018<br /> AJG_Cover-Special-issue2017_v3.indd 1 12/19/17 3:10 PM<br /> VOLUME 113 NUMBER 3 MARCH 2018<br /> www.nature.com/ajg<br /> OFFICIAL PUBLICATION OF THE AMERICAN COLLEGE OF GASTROENTEROLOGY<br /> LEADING ARTICLES OF THE MONTH<br /> Red Section: How I Approach It<br /> 313 Putting Evidence into Practice: IBD Surveillance, Chromoendoscopy<br /> and Future Directions<br /> J.R. ten Hove, C.N. Bernstein and B. Oldenburg<br /> Red Section: Quality Matters<br /> 317 Quality Matters: Improving the Quality of Care for Patients <a title="AJG_Vol.113.No4 page 1" href="http://viewer.zmags.com/publication/4c010226?page=1"> ARCHIVE VOLUME 113 NUMBER 1 JANUARY 2018 www.na</a> <a title="AJG_Vol.113.No4 page 2" href="http://viewer.zmags.com/publication/4c010226?page=2"> VOLUME 113 NUMBER 4 APRIL 2018 www.nature.com/ajg</a> <a title="AJG_Vol.113.No4 page 3" href="http://viewer.zmags.com/publication/4c010226?page=3"> Help adult patients with IBS-D break free from </a> <a title="AJG_Vol.113.No4 page 4" href="http://viewer.zmags.com/publication/4c010226?page=4"> BRIEF SUMMARY OF PRESCRIBING INFORMATION This Bri</a> <a title="AJG_Vol.113.No4 page 5" href="http://viewer.zmags.com/publication/4c010226?page=5"> www.nature.com/ajg The American Journal o</a> <a title="AJG_Vol.113.No4 page 6" href="http://viewer.zmags.com/publication/4c010226?page=6"> Cologuard® lets you deliver cutting-edge science </a> <a title="AJG_Vol.113.No4 page 7" href="http://viewer.zmags.com/publication/4c010226?page=7"> official publication of the american college</a> <a title="AJG_Vol.113.No4 page 8" href="http://viewer.zmags.com/publication/4c010226?page=8"> Attend an upcoming 2018 ACG POSTGRADUATE COUR</a> <a title="AJG_Vol.113.No4 page 9" href="http://viewer.zmags.com/publication/4c010226?page=9"> ÌÊœőŒř ANNUAL SCIENTIFIC MEETING & POSTGRADU</a> <a title="AJG_Vol.113.No4 page 10" href="http://viewer.zmags.com/publication/4c010226?page=10"> Learn more at WWW.MAVYRET.COM FOR CHRONIC HCV I</a> <a title="AJG_Vol.113.No4 page 11" href="http://viewer.zmags.com/publication/4c010226?page=11"> MAVYRETTM (glecaprevir and pibrentasvir) tablets,</a> <a title="AJG_Vol.113.No4 page 12" href="http://viewer.zmags.com/publication/4c010226?page=12"> No adverse embryo-fetal effects were observed in </a> <a title="AJG_Vol.113.No4 page 13" href="http://viewer.zmags.com/publication/4c010226?page=13"> Training in Scientific Writing and Publishing With</a> <a title="AJG_Vol.113.No4 page 14" href="http://viewer.zmags.com/publication/4c010226?page=14"> IMPORTANT SAFETY INFORMATION SUPREP® Bowel Prep K</a> <a title="AJG_Vol.113.No4 page 15" href="http://viewer.zmags.com/publication/4c010226?page=15"> #1 MOST PRESCRIBED, BRANDED BOWEL PREP KIT1 </a> <a title="AJG_Vol.113.No4 page 16" href="http://viewer.zmags.com/publication/4c010226?page=16"> A patient with pure red cell aplasia (PRCA) prese</a> <a title="AJG_Vol.113.No4 page 17" href="http://viewer.zmags.com/publication/4c010226?page=17"> CONTENTS </a> <a title="AJG_Vol.113.No4 page 18" href="http://viewer.zmags.com/publication/4c010226?page=18"> www.nature.com/ajg </a> <a title="AJG_Vol.113.No4 page 19" href="http://viewer.zmags.com/publication/4c010226?page=19"> Indication Trulance (plecanatide) 3 mg tablets is</a> <a title="AJG_Vol.113.No4 page 20" href="http://viewer.zmags.com/publication/4c010226?page=20"> For adults with Chronic Idiopathic Constipation (</a> <a title="AJG_Vol.113.No4 page 21" href="http://viewer.zmags.com/publication/4c010226?page=21"> Trulance® (plecanatide) tablets, for oral use Rx </a> <a title="AJG_Vol.113.No4 page 22" href="http://viewer.zmags.com/publication/4c010226?page=22"> In nonclinical studies, deaths occurred within 24</a> <a title="AJG_Vol.113.No4 page 23" href="http://viewer.zmags.com/publication/4c010226?page=23"> The flagship journal of the American College of Ga</a> <a title="AJG_Vol.113.No4 page 24" href="http://viewer.zmags.com/publication/4c010226?page=24"> Sofosbuvir-based therapy changed expectations in </a> <a title="AJG_Vol.113.No4 page 25" href="http://viewer.zmags.com/publication/4c010226?page=25"> FOR TREATING CHRONIC HCV GT 1 BE THE ONE WHO </a> <a title="AJG_Vol.113.No4 page 26" href="http://viewer.zmags.com/publication/4c010226?page=26"> FOR TREATING CHRONIC HCV EXPAND WHAT'S POSSIBL</a> <a title="AJG_Vol.113.No4 page 27" href="http://viewer.zmags.com/publication/4c010226?page=27"> HARVONI® (ledipasvir 90 mg and sofosbuvir 400 mg)</a> <a title="AJG_Vol.113.No4 page 28" href="http://viewer.zmags.com/publication/4c010226?page=28"> Brief Summary (cont.) •Laboratory Abnormalities</a> <a title="AJG_Vol.113.No4 page 29" href="http://viewer.zmags.com/publication/4c010226?page=29"> EPCLUSA® (sofosbuvir 400 mg and velpatasvir 100 m</a> <a title="AJG_Vol.113.No4 page 30" href="http://viewer.zmags.com/publication/4c010226?page=30"> Brief Summary (cont.) In ASTRAL-1, isolated, asym</a> <a title="AJG_Vol.113.No4 page 31" href="http://viewer.zmags.com/publication/4c010226?page=31"> RECOMMEND THE BEST WITH NEXIUM® 24HR Nexium® 24HR</a> <a title="AJG_Vol.113.No4 page 32" href="http://viewer.zmags.com/publication/4c010226?page=32"> THE RED SECTION 449 see related editorial</a> <a title="AJG_Vol.113.No4 page 33" href="http://viewer.zmags.com/publication/4c010226?page=33"> 450 THE RED SECTION with those patients wi</a> <a title="AJG_Vol.113.No4 page 34" href="http://viewer.zmags.com/publication/4c010226?page=34"> Although the currently available treatment r</a> <a title="AJG_Vol.113.No4 page 35" href="http://viewer.zmags.com/publication/4c010226?page=35"> 452 THE RED SECTION HOW I APPROACH IT THE KE</a> <a title="AJG_Vol.113.No4 page 36" href="http://viewer.zmags.com/publication/4c010226?page=36"> THE RED SECTION 453 see related editorial</a> <a title="AJG_Vol.113.No4 page 37" href="http://viewer.zmags.com/publication/4c010226?page=37"> 454 THE RED SECTION </a> <a title="AJG_Vol.113.No4 page 38" href="http://viewer.zmags.com/publication/4c010226?page=38"> THE RED SECTION 455 Table 2. Utilizing the M</a> <a title="AJG_Vol.113.No4 page 39" href="http://viewer.zmags.com/publication/4c010226?page=39"> 456 THE RED SECTION HOW I APPROACH IT CONFLI</a> <a title="AJG_Vol.113.No4 page 40" href="http://viewer.zmags.com/publication/4c010226?page=40"> THE RED SECTION 457 see related editorial</a> <a title="AJG_Vol.113.No4 page 41" href="http://viewer.zmags.com/publication/4c010226?page=41"> 458 THE RED SECTION DIGITAL DIALOGUE Table 1</a> <a title="AJG_Vol.113.No4 page 42" href="http://viewer.zmags.com/publication/4c010226?page=42"> THE RED SECTION 459 see related editorial</a> <a title="AJG_Vol.113.No4 page 43" href="http://viewer.zmags.com/publication/4c010226?page=43"> 460 THE RED SECTION </a> <a title="AJG_Vol.113.No4 page 44" href="http://viewer.zmags.com/publication/4c010226?page=44"> OPPORTUNITIES FOR SURGEONS TO IMPROVE </a> <a title="AJG_Vol.113.No4 page 45" href="http://viewer.zmags.com/publication/4c010226?page=45"> 462 THE RED SECTION Images of the Month G</a> <a title="AJG_Vol.113.No4 page 46" href="http://viewer.zmags.com/publication/4c010226?page=46"> THE RED SECTION 463 Video of the Month Use </a> <a title="AJG_Vol.113.No4 page 47" href="http://viewer.zmags.com/publication/4c010226?page=47"> 464 CLINICAL GUIDELINES CME ACG Clinical</a> <a title="AJG_Vol.113.No4 page 48" href="http://viewer.zmags.com/publication/4c010226?page=48"> Management decisions for pancreatic cysts must t</a> <a title="AJG_Vol.113.No4 page 49" href="http://viewer.zmags.com/publication/4c010226?page=49"> 466 Elta et al. Table 1. Summary and stren</a> <a title="AJG_Vol.113.No4 page 50" href="http://viewer.zmags.com/publication/4c010226?page=50"> Pancreatic cysts 467 Table 2. Characteristi</a> <a title="AJG_Vol.113.No4 page 51" href="http://viewer.zmags.com/publication/4c010226?page=51"> Is there a history of pancreatitis? Probab</a> <a title="AJG_Vol.113.No4 page 52" href="http://viewer.zmags.com/publication/4c010226?page=52"> Pancreatic cysts 469 What is the largest </a> <a title="AJG_Vol.113.No4 page 53" href="http://viewer.zmags.com/publication/4c010226?page=53"> 470 Elta et al. diagnosing cyst type is 40</a> <a title="AJG_Vol.113.No4 page 54" href="http://viewer.zmags.com/publication/4c010226?page=54"> from causes unrelated to their IPMNs, and are unl</a> <a title="AJG_Vol.113.No4 page 55" href="http://viewer.zmags.com/publication/4c010226?page=55"> 472 Elta et al. for identifying high-grad</a> <a title="AJG_Vol.113.No4 page 56" href="http://viewer.zmags.com/publication/4c010226?page=56"> 12. Patients with a solid-pseudopapillary neoplas</a> <a title="AJG_Vol.113.No4 page 57" href="http://viewer.zmags.com/publication/4c010226?page=57"> 474 Elta et al. There is ongoing debate a</a> <a title="AJG_Vol.113.No4 page 58" href="http://viewer.zmags.com/publication/4c010226?page=58"> presumed IPMNs and MCNs (Figure 2; Conditional re</a> <a title="AJG_Vol.113.No4 page 59" href="http://viewer.zmags.com/publication/4c010226?page=59"> 476 Elta et al. an individualized decisio</a> <a title="AJG_Vol.113.No4 page 60" href="http://viewer.zmags.com/publication/4c010226?page=60"> CONFLICT OF INTEREST </a> <a title="AJG_Vol.113.No4 page 61" href="http://viewer.zmags.com/publication/4c010226?page=61"> 478 Elta et al. 45. Al-Haddad M, Gill KR,</a> <a title="AJG_Vol.113.No4 page 62" href="http://viewer.zmags.com/publication/4c010226?page=62"> 94. Waters JA, Schmidt CM, Pinchot JW et al. CT </a> <a title="AJG_Vol.113.No4 page 63" href="http://viewer.zmags.com/publication/4c010226?page=63"> 480 CONTINUING MEDICAL EDUCATION CME CON</a> <a title="AJG_Vol.113.No4 page 64" href="http://viewer.zmags.com/publication/4c010226?page=64"> CLINICAL GUIDELINES 481 CME ACG Clinical</a> <a title="AJG_Vol.113.No4 page 65" href="http://viewer.zmags.com/publication/4c010226?page=65"> 482 Lichtenstein et al. Development, and </a> <a title="AJG_Vol.113.No4 page 66" href="http://viewer.zmags.com/publication/4c010226?page=66"> Management of Crohn’s Disease in Adults 483 </a> <a title="AJG_Vol.113.No4 page 67" href="http://viewer.zmags.com/publication/4c010226?page=67"> 484 Lichtenstein et al. Table 1. Continued</a> <a title="AJG_Vol.113.No4 page 68" href="http://viewer.zmags.com/publication/4c010226?page=68"> Management of Crohn’s Disease in Adults 485 </a> <a title="AJG_Vol.113.No4 page 69" href="http://viewer.zmags.com/publication/4c010226?page=69"> 486 Lichtenstein et al. Table 2. Summary s</a> <a title="AJG_Vol.113.No4 page 70" href="http://viewer.zmags.com/publication/4c010226?page=70"> Management of Crohn’s Disease in Adults 487 </a> <a title="AJG_Vol.113.No4 page 71" href="http://viewer.zmags.com/publication/4c010226?page=71"> 488 Lichtenstein et al. Table 2. Continued</a> <a title="AJG_Vol.113.No4 page 72" href="http://viewer.zmags.com/publication/4c010226?page=72"> In Crohn’s disease, the 5-year rate of symptomati</a> <a title="AJG_Vol.113.No4 page 73" href="http://viewer.zmags.com/publication/4c010226?page=73"> 490 Lichtenstein et al. CD is a heteroge</a> <a title="AJG_Vol.113.No4 page 74" href="http://viewer.zmags.com/publication/4c010226?page=74"> may be seen in up to 30% of patients with CD, mak</a> <a title="AJG_Vol.113.No4 page 75" href="http://viewer.zmags.com/publication/4c010226?page=75"> 492 Lichtenstein et al. There was hope </a> <a title="AJG_Vol.113.No4 page 76" href="http://viewer.zmags.com/publication/4c010226?page=76"> abscess drainage preoperatively that may lead to </a> <a title="AJG_Vol.113.No4 page 77" href="http://viewer.zmags.com/publication/4c010226?page=77"> 494 Lichtenstein et al. Periodic cross-se</a> <a title="AJG_Vol.113.No4 page 78" href="http://viewer.zmags.com/publication/4c010226?page=78"> associated with a reduced risk of a flare (149). </a> <a title="AJG_Vol.113.No4 page 79" href="http://viewer.zmags.com/publication/4c010226?page=79"> 496 Lichtenstein et al. Working definition</a> <a title="AJG_Vol.113.No4 page 80" href="http://viewer.zmags.com/publication/4c010226?page=80"> General approaches Medical treatment of CD is usu</a> <a title="AJG_Vol.113.No4 page 81" href="http://viewer.zmags.com/publication/4c010226?page=81"> 498 Lichtenstein et al. in patients with </a> <a title="AJG_Vol.113.No4 page 82" href="http://viewer.zmags.com/publication/4c010226?page=82"> narrow angle glaucoma, acne, weight gain, hypoadr</a> <a title="AJG_Vol.113.No4 page 83" href="http://viewer.zmags.com/publication/4c010226?page=83"> 500 Lichtenstein et al. 26. Combination th</a> <a title="AJG_Vol.113.No4 page 84" href="http://viewer.zmags.com/publication/4c010226?page=84"> Insufficient data exist to support the safety</a> <a title="AJG_Vol.113.No4 page 85" href="http://viewer.zmags.com/publication/4c010226?page=85"> 502 Lichtenstein et al. moderately to sev</a> <a title="AJG_Vol.113.No4 page 86" href="http://viewer.zmags.com/publication/4c010226?page=86"> 40. Antibiotics (imidazoles) may be effective and</a> <a title="AJG_Vol.113.No4 page 87" href="http://viewer.zmags.com/publication/4c010226?page=87"> 504 Lichtenstein et al. presence of any a</a> <a title="AJG_Vol.113.No4 page 88" href="http://viewer.zmags.com/publication/4c010226?page=88"> would be realized with azathioprine in an adult p</a> <a title="AJG_Vol.113.No4 page 89" href="http://viewer.zmags.com/publication/4c010226?page=89"> 506 Lichtenstein et al. CD, and numerous </a> <a title="AJG_Vol.113.No4 page 90" href="http://viewer.zmags.com/publication/4c010226?page=90"> cigarette smoking, and all patients should be str</a> <a title="AJG_Vol.113.No4 page 91" href="http://viewer.zmags.com/publication/4c010226?page=91"> 508 Lichtenstein et al. recurrence or for</a> <a title="AJG_Vol.113.No4 page 92" href="http://viewer.zmags.com/publication/4c010226?page=92"> individuals who switch to therapy within class ha</a> <a title="AJG_Vol.113.No4 page 93" href="http://viewer.zmags.com/publication/4c010226?page=93"> 510 Lichtenstein et al. 25. Bewtra M, Kai</a> <a title="AJG_Vol.113.No4 page 94" href="http://viewer.zmags.com/publication/4c010226?page=94"> 76. Rahman A, Ross A, Leighton J et al. Double-b</a> <a title="AJG_Vol.113.No4 page 95" href="http://viewer.zmags.com/publication/4c010226?page=95"> 512 Lichtenstein et al. 122. Wright E, Kam</a> <a title="AJG_Vol.113.No4 page 96" href="http://viewer.zmags.com/publication/4c010226?page=96"> 170. Lim WC, Hanauer S.. Aminosalicylates for ind</a> <a title="AJG_Vol.113.No4 page 97" href="http://viewer.zmags.com/publication/4c010226?page=97"> 514 Lichtenstein et al. 219. Hanauer SB, F</a> <a title="AJG_Vol.113.No4 page 98" href="http://viewer.zmags.com/publication/4c010226?page=98"> 270. Sandborn WJ, Rutgeerts P, Enns R et al. Adal</a> <a title="AJG_Vol.113.No4 page 99" href="http://viewer.zmags.com/publication/4c010226?page=99"> 516 Lichtenstein et al. 320. Lichtenstein </a> <a title="AJG_Vol.113.No4 page 100" href="http://viewer.zmags.com/publication/4c010226?page=100"> 369. Garcia JC, Persky SE, Bonis PA et al. Absces</a> <a title="AJG_Vol.113.No4 page 101" href="http://viewer.zmags.com/publication/4c010226?page=101"> 518 CONTINUING MEDICAL EDUCATION CME CON</a> <a title="AJG_Vol.113.No4 page 102" href="http://viewer.zmags.com/publication/4c010226?page=102"> CLINICAL AND SYSTEMATIC REVIEWS 519 CME D</a> <a title="AJG_Vol.113.No4 page 103" href="http://viewer.zmags.com/publication/4c010226?page=103"> 520 Targownik Stroke REVIEW Lungs (pneu</a> <a title="AJG_Vol.113.No4 page 104" href="http://viewer.zmags.com/publication/4c010226?page=104"> ing affects every observational trial, and it bec</a> <a title="AJG_Vol.113.No4 page 105" href="http://viewer.zmags.com/publication/4c010226?page=105"> 522 Targownik REVIEW adverse events in the </a> <a title="AJG_Vol.113.No4 page 106" href="http://viewer.zmags.com/publication/4c010226?page=106"> in bone homeostasis and in maintaining bone stren</a> <a title="AJG_Vol.113.No4 page 107" href="http://viewer.zmags.com/publication/4c010226?page=107"> 524 Targownik REVIEW risk of peptic ulcer d</a> <a title="AJG_Vol.113.No4 page 108" href="http://viewer.zmags.com/publication/4c010226?page=108"> and physician behaviors that drive inappropriate </a> <a title="AJG_Vol.113.No4 page 109" href="http://viewer.zmags.com/publication/4c010226?page=109"> 526 Targownik REVIEW One strategy to mit</a> <a title="AJG_Vol.113.No4 page 110" href="http://viewer.zmags.com/publication/4c010226?page=110"> 30. Teramura-Gronblad M, Hosia-Randell H, Muurin</a> <a title="AJG_Vol.113.No4 page 111" href="http://viewer.zmags.com/publication/4c010226?page=111"> 528 Targownik REVIEW 77. Masclee GM, Colom</a> <a title="AJG_Vol.113.No4 page 112" href="http://viewer.zmags.com/publication/4c010226?page=112"> CLINICAL AND SYSTEMATIC REVIEWS 529 CME </a> <a title="AJG_Vol.113.No4 page 113" href="http://viewer.zmags.com/publication/4c010226?page=113"> 530 Tapper et al. REVIEW Search MEDLINE (2,</a> <a title="AJG_Vol.113.No4 page 114" href="http://viewer.zmags.com/publication/4c010226?page=114"> Point-of-care tests for MHE are promising tools </a> <a title="AJG_Vol.113.No4 page 115" href="http://viewer.zmags.com/publication/4c010226?page=115"> 532 Tapper et al. REVIEW Table 2. Character</a> <a title="AJG_Vol.113.No4 page 116" href="http://viewer.zmags.com/publication/4c010226?page=116"> Other notable inclusion/exclusion criteria. With </a> <a title="AJG_Vol.113.No4 page 117" href="http://viewer.zmags.com/publication/4c010226?page=117"> 534 Tapper et al. Bajaj et al. (19) </a> <a title="AJG_Vol.113.No4 page 118" href="http://viewer.zmags.com/publication/4c010226?page=118"> Point-of-care tests for MHE are promising tools </a> <a title="AJG_Vol.113.No4 page 119" href="http://viewer.zmags.com/publication/4c010226?page=119"> 536 Tapper et al. REVIEW Table 5. Other mod</a> <a title="AJG_Vol.113.No4 page 120" href="http://viewer.zmags.com/publication/4c010226?page=120"> Variable reference standards There is no universa</a> <a title="AJG_Vol.113.No4 page 121" href="http://viewer.zmags.com/publication/4c010226?page=121"> 538 Tapper et al. REVIEW 3. Tapper EB, Hal</a> <a title="AJG_Vol.113.No4 page 122" href="http://viewer.zmags.com/publication/4c010226?page=122"> ORIGINAL CONTRIBUTIONS 539 see related edi</a> <a title="AJG_Vol.113.No4 page 123" href="http://viewer.zmags.com/publication/4c010226?page=123"> 540 Glasinovic et al. ESOPHAGUS and regurgi</a> <a title="AJG_Vol.113.No4 page 124" href="http://viewer.zmags.com/publication/4c010226?page=124"> symptoms was discussed with the patient to identi</a> <a title="AJG_Vol.113.No4 page 125" href="http://viewer.zmags.com/publication/4c010226?page=125"> 542 Glasinovic et al. 10,000 1,000</a> <a title="AJG_Vol.113.No4 page 126" href="http://viewer.zmags.com/publication/4c010226?page=126"> Supragastric Belching Treatment with Cognitive Be</a> <a title="AJG_Vol.113.No4 page 127" href="http://viewer.zmags.com/publication/4c010226?page=127"> 544 Glasinovic et al. Supragastric belche</a> <a title="AJG_Vol.113.No4 page 128" href="http://viewer.zmags.com/publication/4c010226?page=128"> Table 2. Health-related quality of life pre CBT a</a> <a title="AJG_Vol.113.No4 page 129" href="http://viewer.zmags.com/publication/4c010226?page=129"> 546 Glasinovic et al. ESOPHAGUS CONCLUSION </a> <a title="AJG_Vol.113.No4 page 130" href="http://viewer.zmags.com/publication/4c010226?page=130"> 27. Levy RL, Olden KW, Naliboff BD et al. Psychos</a> <a title="AJG_Vol.113.No4 page 131" href="http://viewer.zmags.com/publication/4c010226?page=131"> 548 ORIGINAL CONTRIBUTION </a> <a title="AJG_Vol.113.No4 page 132" href="http://viewer.zmags.com/publication/4c010226?page=132"> may act as a nidus for subsequent recurrent CBD s</a> <a title="AJG_Vol.113.No4 page 133" href="http://viewer.zmags.com/publication/4c010226?page=133"> 550 D-W Ahn et al ENDOSCOPY case, residual </a> <a title="AJG_Vol.113.No4 page 134" href="http://viewer.zmags.com/publication/4c010226?page=134"> Effects of saline irrigation on residual stones </a> <a title="AJG_Vol.113.No4 page 135" href="http://viewer.zmags.com/publication/4c010226?page=135"> 552 D-W Ahn et al ENDOSCOPY Table 2. Predic</a> <a title="AJG_Vol.113.No4 page 136" href="http://viewer.zmags.com/publication/4c010226?page=136"> Table 4. Procedure-related complications Complica</a> <a title="AJG_Vol.113.No4 page 137" href="http://viewer.zmags.com/publication/4c010226?page=137"> 554 D-W Ahn et al ENDOSCOPY tion, we perfor</a> <a title="AJG_Vol.113.No4 page 138" href="http://viewer.zmags.com/publication/4c010226?page=138"> 17. Ohashi A, Ueno N, Tamada K et al. Assessment </a> <a title="AJG_Vol.113.No4 page 139" href="http://viewer.zmags.com/publication/4c010226?page=139"> 556 ORIGINAL CONTRIBUTIONS see related ed</a> <a title="AJG_Vol.113.No4 page 140" href="http://viewer.zmags.com/publication/4c010226?page=140"> Fungal infections and inpatients with cirrhosis </a> <a title="AJG_Vol.113.No4 page 141" href="http://viewer.zmags.com/publication/4c010226?page=141"> 558 Bajaj et al. LIVER Table 1. Comparison </a> <a title="AJG_Vol.113.No4 page 142" href="http://viewer.zmags.com/publication/4c010226?page=142"> Fungal infections and inpatients with cirrhosis </a> <a title="AJG_Vol.113.No4 page 143" href="http://viewer.zmags.com/publication/4c010226?page=143"> 560 Bajaj et al. a Rat</a> <a title="AJG_Vol.113.No4 page 144" href="http://viewer.zmags.com/publication/4c010226?page=144"> Fungal infections and inpatients with cirrhosis </a> <a title="AJG_Vol.113.No4 page 145" href="http://viewer.zmags.com/publication/4c010226?page=145"> 562 Bajaj et al. 30-day mortality rate ba</a> <a title="AJG_Vol.113.No4 page 146" href="http://viewer.zmags.com/publication/4c010226?page=146"> fungal infections, as they typically occur in tho</a> <a title="AJG_Vol.113.No4 page 147" href="http://viewer.zmags.com/publication/4c010226?page=147"> 564 EDITORIAL see related article on pag</a> <a title="AJG_Vol.113.No4 page 148" href="http://viewer.zmags.com/publication/4c010226?page=148"> not due to Candida infection and treatment of Can</a> <a title="AJG_Vol.113.No4 page 149" href="http://viewer.zmags.com/publication/4c010226?page=149"> 566 Brumble and Keaveny LIVER 12. Hmoud BS,</a> <a title="AJG_Vol.113.No4 page 150" href="http://viewer.zmags.com/publication/4c010226?page=150"> ORIGINAL CONTRIBUTIONS 567 see related ed</a> <a title="AJG_Vol.113.No4 page 151" href="http://viewer.zmags.com/publication/4c010226?page=151"> 568 Neijenhuis et al. LIVER Newer pharm</a> <a title="AJG_Vol.113.No4 page 152" href="http://viewer.zmags.com/publication/4c010226?page=152"> Each individual symptom was assessed with a fr</a> <a title="AJG_Vol.113.No4 page 153" href="http://viewer.zmags.com/publication/4c010226?page=153"> 570 Neijenhuis et al. LIVER Other statistic</a> <a title="AJG_Vol.113.No4 page 154" href="http://viewer.zmags.com/publication/4c010226?page=154"> Validation of an Ascites-Specific Questionnaire </a> <a title="AJG_Vol.113.No4 page 155" href="http://viewer.zmags.com/publication/4c010226?page=155"> 572 Neijenhuis et al. LIVER ascites from re</a> <a title="AJG_Vol.113.No4 page 156" href="http://viewer.zmags.com/publication/4c010226?page=156"> Given that only one-third of patients survive</a> <a title="AJG_Vol.113.No4 page 157" href="http://viewer.zmags.com/publication/4c010226?page=157"> 574 Neijenhuis et al. LIVER to ascites alon</a> <a title="AJG_Vol.113.No4 page 158" href="http://viewer.zmags.com/publication/4c010226?page=158"> 17. Onishi Y, Wakita T, Fukuhara S et al. Develop</a> <a title="AJG_Vol.113.No4 page 159" href="http://viewer.zmags.com/publication/4c010226?page=159"> 576 ORIGINAL CONTRIBUTIONS INFLAMMATORY BOWEL</a> <a title="AJG_Vol.113.No4 page 160" href="http://viewer.zmags.com/publication/4c010226?page=160"> INTRODUCTION Crohn’s disease (CD) is a chronic in</a> <a title="AJG_Vol.113.No4 page 161" href="http://viewer.zmags.com/publication/4c010226?page=161"> 578 M Gajendran et al. INFLAMMATORY BOWEL DI</a> <a title="AJG_Vol.113.No4 page 162" href="http://viewer.zmags.com/publication/4c010226?page=162"> during the 2-year postoperative time period (15).</a> <a title="AJG_Vol.113.No4 page 163" href="http://viewer.zmags.com/publication/4c010226?page=163"> 580 M Gajendran et al. regression coeffic</a> <a title="AJG_Vol.113.No4 page 164" href="http://viewer.zmags.com/publication/4c010226?page=164"> Table 4. Comparison of the endoscopic Rutgeert’s </a> <a title="AJG_Vol.113.No4 page 165" href="http://viewer.zmags.com/publication/4c010226?page=165"> 582 M Gajendran et al. INFLAMMATORY BOWEL DI</a> <a title="AJG_Vol.113.No4 page 166" href="http://viewer.zmags.com/publication/4c010226?page=166"> Institute (5TL1TR000145-09 to AMA; PI: Steven Rei</a> <a title="AJG_Vol.113.No4 page 167" href="http://viewer.zmags.com/publication/4c010226?page=167"> 584 ORIGINAL CONTRIBUTIONS FUNCTIONAL GI DISO</a> <a title="AJG_Vol.113.No4 page 168" href="http://viewer.zmags.com/publication/4c010226?page=168"> Investigation of sensorimotor function under ex</a> <a title="AJG_Vol.113.No4 page 169" href="http://viewer.zmags.com/publication/4c010226?page=169"> 586 Hammer FUNCTIONAL GI DISORDERS Timing o</a> <a title="AJG_Vol.113.No4 page 170" href="http://viewer.zmags.com/publication/4c010226?page=170"> Chemical Sensitivity in GI disorders 587 Ta</a> <a title="AJG_Vol.113.No4 page 171" href="http://viewer.zmags.com/publication/4c010226?page=171"> 588 Hammer GI DISORDERS FUNCTIONAL Table 3.</a> <a title="AJG_Vol.113.No4 page 172" href="http://viewer.zmags.com/publication/4c010226?page=172"> Chemical Sensitivity in GI disorders 589 Ta</a> <a title="AJG_Vol.113.No4 page 173" href="http://viewer.zmags.com/publication/4c010226?page=173"> 590 Hammer 40 35 FUNCTIONAL GI DISORDE</a> <a title="AJG_Vol.113.No4 page 174" href="http://viewer.zmags.com/publication/4c010226?page=174"> be evaluated due to the low number of patients ta</a> <a title="AJG_Vol.113.No4 page 175" href="http://viewer.zmags.com/publication/4c010226?page=175"> 592 Hammer FUNCTIONAL GI DISORDERS 4. Russ</a> <a title="AJG_Vol.113.No4 page 176" href="http://viewer.zmags.com/publication/4c010226?page=176"> ORIGINAL CONTRIBUTIONS 593 see related ed</a> <a title="AJG_Vol.113.No4 page 177" href="http://viewer.zmags.com/publication/4c010226?page=177"> 594 Singh et al. FUNCTIONAL GI DISORDERS st</a> <a title="AJG_Vol.113.No4 page 178" href="http://viewer.zmags.com/publication/4c010226?page=178"> Table 1. Comparison between stool consistency and</a> <a title="AJG_Vol.113.No4 page 179" href="http://viewer.zmags.com/publication/4c010226?page=179"> 596 Singh et al. GI DISORDERS FUNCTIONAL Ta</a> <a title="AJG_Vol.113.No4 page 180" href="http://viewer.zmags.com/publication/4c010226?page=180"> Chronic diarrhea in USA 597 Table 2. Contin</a> <a title="AJG_Vol.113.No4 page 181" href="http://viewer.zmags.com/publication/4c010226?page=181"> 598 Singh et al. GI DISORDERS FUNCTIONAL Ta</a> <a title="AJG_Vol.113.No4 page 182" href="http://viewer.zmags.com/publication/4c010226?page=182"> addition, polypharmacy is more common among the e</a> <a title="AJG_Vol.113.No4 page 183" href="http://viewer.zmags.com/publication/4c010226?page=183"> 600 Singh et al. FUNCTIONAL GI DISORDERS 12</a> <a title="AJG_Vol.113.No4 page 184" href="http://viewer.zmags.com/publication/4c010226?page=184"> ORIGINAL CONTRIBUTIONS 601 see related edi</a> <a title="AJG_Vol.113.No4 page 185" href="http://viewer.zmags.com/publication/4c010226?page=185"> 602 Kang et al. COLON/SMALL BOWEL INTRODUCT</a> <a title="AJG_Vol.113.No4 page 186" href="http://viewer.zmags.com/publication/4c010226?page=186"> ing data were collected before colonoscopy, inclu</a> <a title="AJG_Vol.113.No4 page 187" href="http://viewer.zmags.com/publication/4c010226?page=187"> 604 Kang et al. COLON/SMALL BOWEL 2,532 pat</a> <a title="AJG_Vol.113.No4 page 188" href="http://viewer.zmags.com/publication/4c010226?page=188"> Table 1. Baseline characteristics SSL group </a> <a title="AJG_Vol.113.No4 page 189" href="http://viewer.zmags.com/publication/4c010226?page=189"> 606 Kang et al. COLON/SMALL BOWEL Table 2. </a> <a title="AJG_Vol.113.No4 page 190" href="http://viewer.zmags.com/publication/4c010226?page=190"> SSL group Standard group Age 50 years </a> <a title="AJG_Vol.113.No4 page 191" href="http://viewer.zmags.com/publication/4c010226?page=191"> 608 Kang et al. COLON/SMALL BOWEL Table 4. </a> <a title="AJG_Vol.113.No4 page 192" href="http://viewer.zmags.com/publication/4c010226?page=192"> Study Highlights WHAT IS CURRENT KNOWLEDGE ✓ Hig</a> <a title="AJG_Vol.113.No4 page 193" href="http://viewer.zmags.com/publication/4c010226?page=193"> 610 Kang et al. COLON/SMALL BOWEL 38. Chung</a> <a title="AJG_Vol.113.No4 page 194" href="http://viewer.zmags.com/publication/4c010226?page=194"> ORIGINAL CONTRIBUTIONS 611 see related ed</a> <a title="AJG_Vol.113.No4 page 195" href="http://viewer.zmags.com/publication/4c010226?page=195"> 612 JM Cha et al. COLON/SMALL BOWEL has bee</a> <a title="AJG_Vol.113.No4 page 196" href="http://viewer.zmags.com/publication/4c010226?page=196"> colon (C19) and rectum (C20). Other cancer was de</a> <a title="AJG_Vol.113.No4 page 197" href="http://viewer.zmags.com/publication/4c010226?page=197"> 614 JM Cha et al. Table 1. Percentage of pos</a> <a title="AJG_Vol.113.No4 page 198" href="http://viewer.zmags.com/publication/4c010226?page=198"> Interval Cancer Risk of Screening FIT 615 </a> <a title="AJG_Vol.113.No4 page 199" href="http://viewer.zmags.com/publication/4c010226?page=199"> 616 JM Cha et al. Table 2. Performance param</a> <a title="AJG_Vol.113.No4 page 200" href="http://viewer.zmags.com/publication/4c010226?page=200"> Interval Cancer Risk of Screening FIT Table 3. P</a> <a title="AJG_Vol.113.No4 page 201" href="http://viewer.zmags.com/publication/4c010226?page=201"> 618 JM Cha et al. Table 4. Performance param</a> <a title="AJG_Vol.113.No4 page 202" href="http://viewer.zmags.com/publication/4c010226?page=202"> Table 5. Interval cancer according to anatomical </a> <a title="AJG_Vol.113.No4 page 203" href="http://viewer.zmags.com/publication/4c010226?page=203"> 620 JM Cha et al. COLON/SMALL BOWEL CONFLIC</a> <a title="AJG_Vol.113.No4 page 204" href="http://viewer.zmags.com/publication/4c010226?page=204"> 24. Lee J. K., Liles E. G., Bent S., Levin T. R.,</a> <a title="AJG_Vol.113.No4 page 205" href="http://viewer.zmags.com/publication/4c010226?page=205"> 622 LETTERS TO THE EDITOR Pathophysiolo</a> <a title="AJG_Vol.113.No4 page 206" href="http://viewer.zmags.com/publication/4c010226?page=206"> (AEEH)” meetings (2011–2017), including pharmaceu</a> <a title="AJG_Vol.113.No4 page 207" href="http://viewer.zmags.com/publication/4c010226?page=207"> 624 Letters to the Editor 3. Talley NJ. A</a> <a title="AJG_Vol.113.No4 page 208" href="http://viewer.zmags.com/publication/4c010226?page=208"> cholecystectomy should be carried out as a first </a> <a title="AJG_Vol.113.No4 page 209" href="http://viewer.zmags.com/publication/4c010226?page=209"> 626 Letters to the Editor </a> <a title="AJG_Vol.113.No4 page 210" href="http://viewer.zmags.com/publication/4c010226?page=210"> USA; exclusion of large APC deletions or duplicat</a> <a title="AJG_Vol.113.No4 page 211" href="http://viewer.zmags.com/publication/4c010226?page=211"> 628 Letters to the Editor dose escalation </a> <a title="AJG_Vol.113.No4 page 212" href="http://viewer.zmags.com/publication/4c010226?page=212"> endoscopy was not performed in the interim period</a> <a title="AJG_Vol.113.No4 page 213" href="http://viewer.zmags.com/publication/4c010226?page=213"> 630 Letters to the Editor </a> <a title="AJG_Vol.113.No4 page 214" href="http://viewer.zmags.com/publication/4c010226?page=214"> Figure 2. (a) Active chronic inflammatory changes,</a> <a title="AJG_Vol.113.No4 page 215" href="http://viewer.zmags.com/publication/4c010226?page=215"> 632 Letters to the Editor in immuncompromi</a> <a title="AJG_Vol.113.No4 page 216" href="http://viewer.zmags.com/publication/4c010226?page=216"> pression, she was initiated on vedolizumab (Entyv</a> <a title="AJG_Vol.113.No4 page 217" href="http://viewer.zmags.com/publication/4c010226?page=217"> 634 ANNOUNCEMENTS CALENDAR OF COURSES, </a> <a title="AJG_Vol.113.No4 page 218" href="http://viewer.zmags.com/publication/4c010226?page=218"> Improve your written English to help your researc</a> <a title="AJG_Vol.113.No4 page 219" href="http://viewer.zmags.com/publication/4c010226?page=219"> CLASSIFIEDS Ed Z KEzKh FIND YOU</a> <a title="AJG_Vol.113.No4 page 220" href="http://viewer.zmags.com/publication/4c010226?page=220"> ACG MOBILE:ACCESS KEY RESOURCES </a> <a title="AJG_Vol.113.No4 page 221" href="http://viewer.zmags.com/publication/4c010226?page=221"> </a>